---
title: "Lupin Tops Global Pharma and India Rankings in S&P ESG Assessment 2025"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277030493.md"
description: "Lupin Limited has been ranked as the top pharmaceutical company globally and the leading company in India in the S&P Global Corporate Sustainability Assessment 2025, achieving a score of 91 out of 100. This recognition places Lupin in the top 1% of companies worldwide and secures its inclusion in the S&P Global Sustainability Yearbook 2026 for the third consecutive year. The achievement highlights Lupin's commitment to integrating ESG principles and enhancing its reputation among investors and regulators."
datetime: "2026-02-26T11:26:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277030493.md)
  - [en](https://longbridge.com/en/news/277030493.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277030493.md)
---

# Lupin Tops Global Pharma and India Rankings in S&P ESG Assessment 2025

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Lupin Limited ( (IN:LUPIN) ) has issued an announcement.

Lupin Limited has been ranked the number one pharmaceutical company globally and the top company across all sectors in India in the S&P Global Corporate Sustainability Assessment 2025, with an overall score of 91 out of 100. This places Lupin among the top 1% of companies worldwide in the assessment and secures its inclusion in the S&P Global Sustainability Yearbook 2026 for the third consecutive year.

The recognition underscores Lupin’s position as a global sustainability leader and reflects its strong performance on economic, environmental, and social criteria relative to more than 9,200 companies assessed across 59 industries. Management indicated that this achievement reinforces Lupin’s long-term strategy of integrating ESG principles across its value chain and supports its efforts to drive positive outcomes for patients, communities, and stakeholders, potentially strengthening its reputation with investors and regulators.

**More about Lupin Limited**

Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, focused on developing, manufacturing, and marketing a wide range of generic and branded formulations, as well as active pharmaceutical ingredients. The company serves patients and healthcare systems worldwide and competes with both Indian and international peers across multiple therapeutic areas.

**Average Trading Volume:** 33,145

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** 1028.9B INR

Find detailed analytics on LUPIN stock on TipRanks’ Stock Analysis page.

## Related News & Research

- [Irish economic miracle explained: Why all that glitter isn't gold](https://longbridge.com/en/news/285034065.md)
- [ZAWYA: UAE’s LIFEPharma signs MoU with AD Ports for $190mln pharma manufacturing platform](https://longbridge.com/en/news/285209681.md)
- [Rising Stars: Axplora’s Arsalan Khan gets technical on marketing](https://longbridge.com/en/news/285037850.md)
- [Ultragenyx CFO’s Latest Stock Move Has Investors Buzzing](https://longbridge.com/en/news/285146405.md)
- [3 High Quality Undiscovered Gems With Quietly Strong Cash Engines](https://longbridge.com/en/news/285083415.md)